Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older.
- People who have given written consent to participate in the study.
- People who have been diagnosed with a specific type of blood cancer called APL (Acute Promyelocytic Leukaemia), either as a first-time (primary) or treatment-related (secondary) diagnosis, and who have not yet received any treatment for it.
- People whose APL diagnosis has been confirmed through specific laboratory tests that detect the genetic change associated with this disease (confirm with trial site for exact test requirements).
Who may not be able to join:
- People who currently have another active cancer that also requires treatment at the same time.
- People who have already received any treatment for APL.
- People who have a heart condition called Long QT Syndrome, or whose heart electrical activity (measured by an ECG) shows certain abnormalities, including an irregular heart rhythm or a specific type of electrical conduction problem in the heart (confirm with trial site for exact heart criteria).
- People with a very low level of physical functioning, meaning they are completely bedridden and unable to care for themselves (confirm with trial site).
- People with severe heart failure (classified as Stage III or IV).
- People whose kidneys are not working well enough, based on a specific blood test result, unless the kidney problem is caused by the APL itself.
- People whose liver is not working well enough, based on specific blood test results, unless the liver problem is caused by the APL itself.
- People with a severe psychiatric illness.
- People who are pregnant or who have decided to continue breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: María José Mela Osorio, Dr., Grupo Argentino de Tratamiento de la Leucemia Aguda
Phone: +5491149720765
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate overall survival of patients diagnosed with APL and treated in first line with ATO/ATRA or ATO/ATRA/Idarubicin (IDA).; Evaluate event free survival of patients diagnosed with APL and treated in first line with ATO/ATRA or ATO/ATRA/Idarubicin (IDA).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.